Prognostic factors of noninvasive mechanical ventilation in lung cancer patients with acute respiratory failure

Wei-Chih Chen¹,², Vincent Yi-Fong Su¹,³, Wen-Kuang Yu¹,², Yen-Wen Chen¹,², Kuang-Yao Yang¹,²,⁴*

¹Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ²School of Medicine, National Yang-Ming University, Taipei, Taiwan, ³Department of Internal Medicine, Taipei City Hospital Yangming Branch, Taipei, Taiwan, ⁴Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

* kyyang@vghtpe.gov.tw

Abstract

Introduction
Few studies have reported outcomes of lung cancer patients with acute respiratory failure (RF) using noninvasive positive pressure ventilation (NIPPV). The aim of this study was to investigate the prognostic factors in these patients.

Materials and methods
This retrospective observational study included all hospitalized lung cancer patients who received NIPPV for acute RF. It was conducted at a tertiary medical center in Taiwan from 2005 to 2010. The primary outcome was all cause mortality at 28 days after the initiation of NIPPV. Secondary outcomes included all-cause in-hospital mortality, weaning from NIPPV, intubation rate, tracheostomy rate, duration of NIPPV, hospital stay and intensive care unit stay.

Results
The all-cause mortality rate at day 28 of the enrolled 58 patients was 39.66%. The 90-day and 1-year mortality rates were 63.79% and 86.21%, respectively. NIPPV as the first line therapy for RF had higher 28-day mortality rate than it used for post-extubation RF (57.6% versus 16.0%, p < 0.05). Independent predictors of mortality at 28 days were progressive disease or newly diagnosed lung cancer (OR 14.02 95% CI 1.03–191.59, p = 0.048), combined with other organ failure (OR 18.07 95% CI 1.87–172.7, p = 0.012), and NIPPV as the first line therapy for respiratory failure (OR 35.37 95% CI 3.30–378.68, p = 0.003).

Conclusion
Lung cancer patients using NIPPV with progressive or newly diagnosed cancer disease, combined with other organ failure, or NIPPV as the first line therapy for respiratory failure have a poor outcome.
Introduction
Lung cancer is the major cause of cancer-related death worldwide, reportedly accounting for 12.7% of new cancer cases and 18.2% of cases of cancer-associated mortality[1]. In addition, lung cancer-associated complications result in high rates of morbidity and mortality. A cohort study in two intensive care units (ICU) reported that the main reasons why lung cancer patients were admitted to the ICU included severe sepsis, septic shock, acute respiratory failure and cardiovascular complications, with mortality rates in the ICU and hospital of 42% and 59%, respectively[2]. Acute respiratory failure (RF) is a life-threatening complication of lung cancer patients and is usually associated with a poor prognosis[3]. In the recent Surveillance, Epidemiology, and End Results (SEER) Medicare registry study, 76% of the 49373 patients with lung cancer admitted to an ICU survived hospitalization. However, only 35% of these patients were still alive at 6 months after discharge. Use of mechanical ventilation was associated with an increased risk of mortality[4]. Besides, in the prospective multicenter Lung Cancer in Critical Care (LUCCA) Study, 53% patients required ventilatory support[5].

One of the most frequently encountered complications in critically ill cancer patients is RF [6]. In cancer patients with RF who require ventilator support, endotracheal intubation with invasive mechanical ventilation (IMV) is the most common treatment modality[7]. However, apart from patient discomfort during translaryngeal intubation, several adverse outcomes such as ventilator-associated pneumonia, barotrauma, and tracheal injury are often associated with the use of IMV[8]. To avoid these problems and increase patient comfort, noninvasive positive pressure ventilation (NIPPV) has been adopted in recent years. Previous studies have addressed the benefits of NIPPV in patients with hematologic malignancies and acute RF[9–12], however, few studies have investigated the use of NIPPV for lung cancer patients with acute RF. Meert et al reported that 21% of lung cancer patients in an ICU who used NIPPV as the initial support eventually required intubation, and their discharge rate from hospital was high at 47.4%[13]. In cancer patients with acute hypoxemic RF, NIPPV as first-line therapy with clinical failure had higher mortality compared with IMV[14]. Pulmonary infections and high severity scores had been associated with NIPPV failure[15]. NIPPV failure during acute respiratory distress syndrome in patients with cancer also has increased in-hospital mortality[16]. The aim of this study was to assess NIPPV in lung cancer patients with acute RF and to explore the prognostic factors for outcome analysis.

Materials and methods
Study design and patients
This retrospective study was conducted at Taipei Veterans General Hospital, a tertiary medical center in Taiwan. The investigation included all hospitalized lung cancer patients who received NIPPV for acute RF from January 2005 to September 2010. The diagnosis of lung cancer was established according to pathological evidence. Acute RF was classified into hypercapnia, hypoxemia, and mixed types. Patients using NIPPV after IMV to facilitate weaning from the postoperative care of lung cancer surgery were excluded. The study protocol was approved by the Institutional Review Board of Taipei Veterans General Hospital with a waiver of patient consent and was conducted in accordance with the Helsinki Declaration.

Criteria of NIPPV
In this study, the initiation of NIPPV on acute respiratory failure included presence of one or more of following conditions: (1) severe dyspnea with active contraction of the accessory muscles or paradoxical abdominal movement, (2) tachypnea with rate more than 30 per minute,
(3) poor oxygenation with ratio of partial pressure arterial oxygen and fraction of inspired oxygen less than 200 and respiratory acidosis with pH less than 7.35 and/or (4) partial pressure of carbon dioxide more than 45 mmHg. Instead, IMV was given if the patients have respiratory or cardia arrest, consciousness drowsy or under sedation, massive aspiration, inability to remove secretions, hemodynamic instability or life-threatening arrhythmia.

Data collection and measurements
“Do-Not-Resuscitate” orders, Eastern Cooperative Oncology Group performance status[17], types and causes of acute RF were recorded in addition to demographic data, including age, gender, and comorbidities. Lung cancer-related information such as histology type, staging [18], previous anti-cancer treatment, recent therapy within 2 weeks before events of RF, and cancer status were also recorded. Respiratory and critical care data concerning the initial mode of mechanical ventilation, site of NIPPV use, oxygen therapy before NIPPV, arterial blood gas analysis at the onset of respiratory failure, serum albumin level, presence of organ failure, and severity score were also collected. The main outcome measure was all cause mortality at 28 days after the onset of RF. Secondary outcomes included all cause in-hospital mortality, intubation rate, tracheostomy rate, duration of noninvasive ventilation, hospital stay and ICU stay.

Statistical analysis
The results were presented as mean ± standard deviation, median with interquartile range, or number (%) as appropriate. We used the Kolmogorov-Smirnov and Shapiro-Wilk tests to examine the normality of continuous variables. Independent t tests were used to compare normally distributed continuous variables, and the Mann-Whitney U test was used to compare non-normally distributed continuous variables. We used the Pearson χ² test or the Fisher’s exact test to compare categorical variables. Variables showing with significant differences between groups were entered into univariate and multivariate logistic regression analyses using the enter method to determine factors independently associated with mortality. Odds ratios and 95% confidence intervals were also calculated. A P value less than 0.05 was considered to be statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (version 19.0, SPSS Inc., Chicago, IL).

Results
Patient characteristics and critical illness factors between survivors and non-survivors
During the study period, 326 lung cancer patients received noninvasive ventilation therapy, of whom 247 patients were excluded owing to the use of noninvasive ventilation to facilitate extubation after thoracic surgery without evidence of post-extubation RF and 21 patients were excluded due to inadequate medical records, respectively. The remaining 58 patients were enrolled in the study, 35 of whom survived to day 28 (Fig 1). The characteristics of the patients are shown in Table 1. Respiratory status and cause of respiratory failure at NIPPV initiation are shown in S1 and S2 Tables. Survivors had significantly less advanced lung cancer and more stable disease or disease that was responsive to anti-cancer therapy. The critical illness-related factors are shown in Table 2. Survivors presented with more non-cancer-related RF and absence of other organ failure. In addition, NIPPV was used more often as the first line therapy for RF.
Outcomes of the enrolled patients

The all-cause mortality rate at day 28 after the initiation of NIPPV was 39.66%, and the 90-day and 1-year mortality rates were 63.79% and 86.21%, respectively. Outcomes of the enrolled patients are presented in Table 3. Survivors had a significantly longer hospital stay than non-survivors; however, there were no significant differences in intubation rate, tracheostomy rate, duration of NIPPV, or ICU stay.

To further elucidate clinical predictors of mortality among lung cancer patients with NIPPV, we used univariate and multivariate logistic regression analyses (Table 4). Significant variables including terminal stage, progressive disease or newly diagnosed lung cancer, cancer- or treatment-related respiratory failure, NIPPV as first line therapy for RF, and combined with other organ failure. Progressive disease or newly diagnosed lung cancer (OR 14.02, CI [1.03–191.59], p = 0.048), NIPPV as the first line therapy for RF (OR 35.37, CI [3.30–378.68], p = 0.003) and combined with other organ failure (OR 18.07, CI [1.89–172.7], p = 0.012) remained independent predictors after multivariate regression analysis.

Kaplan-Meier analysis (Fig 2) shows poor survival among the patients initiating NIPPV as first line therapy for RF (log-rank test p = 0.001). Poorer survival in the patients with progressive disease or newly diagnosed lung cancer (log-rank test p = 0.033) is revealed in S1 Fig. The overall 1-year survival rate of the lung cancer patients with NIPPV was only 13.79% (S2 Fig).
Discussion

In this study, the 28-day mortality and all-cause in-hospital mortality rates were high in adult lung cancer patients who received non-invasive ventilation for acute respiratory failure. The independent predictors for 28-day mortality included progressive disease or newly diagnosed lung cancer, NIPPV as first line therapy for respiratory failure and combined with other organ failure. However, comorbidities, performance status, cancer cell type, severity score, and serum albumin levels were not related to the survival of NIPPV therapy.

Due to different cultural backgrounds and policies of insurance reimbursement, some patients who receive noninvasive ventilation remained in the general ward or hospice ward instead of an ICU in Taiwan. However, the all-cause mortality rates in this study were similar to those in other studies on critically ill lung cancer patients[2,4,13,19–21], ranging from 54% to 59%. Consistent with these studies, mortality was not influenced by where noninvasive ventilation was performed. The 6-month survival rate of lung cancer patients admitted to an ICU has been reported to be 27%[19] to 35%[4] in various studies. In the current study, the 1-year mortality rate of the patients who received noninvasive ventilation was as high as 86.2%, indicating the extremely poor prognosis of such patients.

Table 1. Comparison of patient characteristics between survivors and non-survivors at day 28*

| Variables                           | Survivor (n = 35) | Non-survivor(n = 23) | P value |
|-------------------------------------|------------------|----------------------|---------|
| Age (years)                         | 76.71 ± 9.49     | 75.97 ± 9.22         | 0.721   |
| Gender (M/F)                        | 25/10            | 18/5                 | 0.561   |
| Comorbidities                       |                  |                      |         |
| DM                                  | 8 (22.9%)        | 4 (17.4%)            | 0.746   |
| Hypertension                        | 14 (40%)         | 14 (60.9%)           | 0.120   |
| Chronic cardiovascular disease      | 3 (8.6%)         | 3 (13.0%)            | 0.673   |
| Chronic respiratory disease         | 15 (42.9%)       | 9 (39.1%)            | 0.778   |
| Chronic kidney disease              | 1 (2.9%)         | 4 (17.4%)            | 0.075   |
| Chronic liver disease               | 1 (2.9%)         | 1 (4.3%)             | 1       |
| Performance status                  |                  |                      | 0.145   |
| 0–3                                 | 19 (54.3%)       | 8 (34.8%)            |         |
| 4                                   | 16 (45.7%)       | 15 (65.2%)           |         |
| Cancer cell type                    |                  |                      | 0.129   |
| Small cell lung cancer              | 7 (20%)          | 1 (4.3%)             |         |
| Non-small cell lung cancer          | 28 (80%)         | 22 (95.7%)           |         |
| Stage                               |                  |                      | 0.039   |
| Stage I-III                         | 17 (48.6%)       | 5 (21.7%)            |         |
| Stage IV                            | 18 (51.4%)       | 18 (78.3%)           |         |
| Anti-cancer therapy*                |                  |                      | 0.872   |
| Without anti-cancer therapy         | 10               | 8                    |         |
| With surgery                        | 2                | 1                    |         |
| With target, radio-, or chemo-therapy only | 23               | 14                   |         |
| Tumor status                        |                  |                      | 0.016   |
| Stable disease or responsive to current therapy | 13 (37.1%)       | 2 (8.7%)             |         |
| Progressive disease or newly diagnosed lung cancer | 22 (62.9%)       | 21 (91.3%)           |         |

Data are expressed as mean ± SD or No. (%). DM, diabetes mellitus.
*Survival was defined according to the survival status on day 28 of initiating noninvasive positive pressure ventilation.
*Before initiation of noninvasive positive pressure ventilation.

https://doi.org/10.1371/journal.pone.0191204.t001
Table 2. Comparison of critical illness factors between survivors and non-survivors at day 28°.

| Variables                          | Survivor (n = 35) | Non-survivor (n = 23) | P value |
|------------------------------------|------------------|-----------------------|---------|
| **Types of RF**                    |                  |                       |         |
| Hypoxemic                          | 9 (25.7%)        | 3 (13%)               | 0.490   |
| Hypercapnic                        | 12 (34.3%)       | 10 (43.5%)            |         |
| Mixed                              | 14 (40%)         | 10 (43.5%)            |         |
| **Causes of RF by cancer**         |                  |                       | <0.001  |
| Cancer or treatment-related        | 14 (40.0%)       | 20 (87.0%)            |         |
| Non-cancer-related                 | 21 (60.0%)       | 3 (13.0%)             |         |
| **Severity score**                 |                  |                       |         |
| APACHE II                          | 16.97 ± 5.41     | 20.36 ± 7.89          | 0.073   |
| SAPS II                            | 46.24 ± 11.90    | 48.67 ± 13.19         | 0.487   |
| SOFA                               | 4.91 ± 2.38      | 5.55 ± 3.36           | 0.414   |
| **Reasons for initiating NIPPV use for RF** |                |                       | 0.001   |
| Post-extubation RF                 | 21 (60.0%)       | 4 (17.4%)             |         |
| As the first-line therapy          | 14 (40.0%)       | 19 (82.6%)            |         |
| **Location where NIPPV was performed** |                  |                       | 0.460   |
| General ward                       | 5 (14.3%)        | 3 (13.0%)             |         |
| ICU                                | 30 (85.7%)       | 19 (82.6%)            |         |
| Hospice ward                       | 0                | 1 (4.3%)              |         |
| **Serum albumin levels before NIPPV use (g/dl)** | 2.63 ± 0.64     | 2.64 ± 0.61           | 0.943   |
| **Other organ failure**            |                  |                       |         |
| Shock                              | 4 (11.4%)        | 7 (30.4%)             | 0.093   |
| Renal                              | 10 (28.6%)       | 10 (43.5%)            | 0.243   |
| Liver                              | 4 (11.4%)        | 3 (13.0%)             | 1       |
| Metabolic acidosis                 | 8 (22.9%)        | 4 (17.4%)             | 0.746   |
| Coagulopathy                       | 6 (17.1%)        | 4 (17.4%)             | 1       |
| **Numbers of organ failure**       |                  |                       | 0.034   |
| RF only                            | 19 (54.3%)       | 6 (26.1%)             |         |
| Combined other organ failures      | 16 (45.7%)       | 17 (73.9%)            |         |

Data are expressed as mean ± SD or No. (%). APACHE II, Acute Physiology and Chronic Health Evaluation II score; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIPPV, noninvasive positive pressure ventilation; RF, respiratory failure; SAPS II, Simplified Acute Physiology II Score; SOFA, Sequential Organ Failure Assessment.

*Survival was defined according to the survival status on day 28 of initiating NIPPV.

https://doi.org/10.1371/journal.pone.0191204.t002

Table 3. Comparison of patient outcomes between survivors and non-survivors at day 28°.

| Variables                | Survivors (n = 35) | Non-survivors (n = 23) | P value |
|--------------------------|-------------------|------------------------|---------|
| Hospital mortality       | 8 (22.9%)         | 23 (100%)              | <0.001  |
| Intubation after NIPPV   | 7 (20.0%)         | 5 (21.7%)              | 1       |
| Tracheostomy after NIPPV | 1 (2.9%)          | 0                      | 1       |
| Duration of NIPPV (days) | 11.23 ± 6.98      | 6.35 ± 5.60            | 0.702   |
| Hospital stay (days)     | 41.09 ± 26.37     | 18.91 ± 10.13          | <0.001  |
| ICU stay (days)          | 18.34 ± 17.78     | 12.40 ± 7.11           | 0.228   |

Data are expressed as mean ± SD or No. (%). ICU, intensive care unit; NIPPV, noninvasive positive pressure ventilation.

*Survival was defined according to the survival status on day 28 after initiating NIPPV.

https://doi.org/10.1371/journal.pone.0191204.t003
Both patient characteristics and critical illness-related factors have been reported to have an impact on mortality. In studies on lung cancer patients admitted to an ICU, severe comorbidities[2], poor performance status[14,22], cancer with disease progression[2,14,22], airway obstruction due to cancer, increased organ failure[2,21,22], use of vasopressors[20,21], use of mechanical ventilation[4,19,21], and acute respiratory failure[19] have been associated with increased ICU, hospital and 6-month mortality rates. We also found that NIPPV as first line therapy for RF was associated with an increased 28-day mortality rate. The exact reason for this is unknown; however a possible explanation is that most of our patients suffered from non-cancer-related acute RF with other organ failure and IMV has been reported to be more suitable for these patients[23].

Noninvasive ventilation is also an effective method to facilitate weaning from IMV. In this study, we observed that most patients who received IMV had RF due to non-cancer-related causes, which are often reversible if aggressive treatment is provided. Transitioning from invasive to noninvasive ventilation in such patients is usually performed when their general condition improves. In addition, noninvasive ventilation can prevent many of the complications associated with IMV such as ventilator-associated pneumonia, barotrauma or airway injury. Several clinical trials and meta-analyses have favored the use of noninvasive ventilation after extubation to prevent post-extubation respiratory failure [24–28]. Among these studies, patients with chronic respiratory disorders, especially chronic obstructive pulmonary disease, were found to benefit the most. Due to the high prevalence of chronic respiratory diseases in our patients, using noninvasive ventilation to facilitate the early removal of endotracheal tubes was a reasonable and acceptable therapeutic modality.

There are several limitations to this study. First, our cohort was derived from a single tertiary teaching medical center in Taiwan. Secondly, the relatively small sample size and exclusion of some patients due to inadequate medical records might have biased the results. Third, some patients had "Do-Not-Resuscitate" orders in our study. However, most of our patients signed the non-resuscitation permits after initial stabilization of acute episode, the medical decisions to choose the initial types of mechanical ventilation were not influenced by the DNR order. Finally, because this is a retrospective study, some confounding factors may have been neglected.

In conclusion, progressive disease or newly diagnosed lung cancer and multiple organ failure have poor prognosis. In addition, NIPPV as first line therapy for RF is the most important predictor for 28-day mortality. The relative risk should be considered before initiation of NIPPV in lung cancer patients with acute RF.

### Table 4. Predictors of mortality at day 28 after the onset of respiratory failure using univariate and multivariate logistic regression analyses.

| Variables                                      | Univariate | Multivariate |
|------------------------------------------------|------------|--------------|
|                                                 | Odds ratio | 95% confidence interval | P value | Odds ratio | 95% confidence interval | P value |
| Terminal stage (stage IV)                       | 3.40       | 1.03–11.20  | 0.044    |           |               |         |
| Progressive disease or newly diagnosed lung cancer | 6.21       | 1.25–30.87  | 0.026    | 14.02     | 1.03–191.59    | 0.048   |
| Cancer or treatment-related RF                   | 10.00      | 2.49–40.12  | 0.001    |           |               |         |
| NIPPV as the first line therapy for RF           | 7.125      | 1.995–25.441 | 0.002   | 35.37     | 3.30–378.68    | 0.003   |
| Combined other organ failures                    | 3.37       | 1.07–10.56  | 0.038    | 18.07     | 1.89–172.70    | 0.012   |

IMV, invasive mechanical ventilation; NIPPV, noninvasive positive pressure ventilation; RF, respiratory failure.

https://doi.org/10.1371/journal.pone.0191204.t004
Fig 2. Patients’ survival according to reasons for NIPPV use in respiratory failure.

https://doi.org/10.1371/journal.pone.0191204.g002
Supporting information

S1 Fig. NIPPV Patients’ survival according to tumor status. NIPPV, non-invasive positive pressure ventilation.

(DOC)

S2 Fig. Overall survival after 1-year follow up.

(DOCX)

S1 Table. Respiratory status at NIPPV initiation. NIPPV, non-invasive positive pressure ventilation.

(DOC)

S2 Table. Causes of respiratory failure.

(DOCX)

S3 Table. Predictors of mortality at day 28 after the onset of respiratory failure using univariate and multivariate logistic regression analyses with forward likelihood ratio method.

(DOCX)

S4 Table. NIPPV setting and complications.

(DOC)

Author Contributions

Conceptualization: Wei-Chih Chen, Vincent Yi-Fong Su, Kuang-Yao Yang.

Data curation: Wei-Chih Chen, Kuang-Yao Yang.

Formal analysis: Wei-Chih Chen, Kuang-Yao Yang.

Funding acquisition: Kuang-Yao Yang.

Methodology: Wei-Chih Chen, Wen-Kuang Yu, Yen-Wen Chen, Kuang-Yao Yang.

Project administration: Wei-Chih Chen.

Supervision: Kuang-Yao Yang.

Validation: Wei-Chih Chen, Wen-Kuang Yu, Yen-Wen Chen, Kuang-Yao Yang.

Visualization: Wei-Chih Chen, Wen-Kuang Yu, Yen-Wen Chen, Kuang-Yao Yang.

Writing – original draft: Wei-Chih Chen, Vincent Yi-Fong Su.

Writing – review & editing: Wei-Chih Chen, Kuang-Yao Yang.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893–917. https://doi.org/10.1002/ijc.25516 PMID: 21351289

2. Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, et al. Prognosis of lung cancer patients with life-threatening complications. Chest 2007; 131:840–6. https://doi.org/10.1378/chest.06-2244 PMID: 17356101

3. Ewer MS, Ali MK, Atta MS, Morice RC, Balakrishnan PV. Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure. JAMA 1986; 256:3364–6. PMID: 3783887

4. Slatore CG, Cecere LM, Letourneau JL, O’Neil ME, Duckart JP, Wiener RS, et al. Intensive care unit outcomes among patients with lung cancer in the surveillance, epidemiology, and end results-medicare registry. J Clin Oncol 2012; 30:1686–91. https://doi.org/10.1200/JCO.2011.40.0846 PMID: 22473159
5. Soares M, Toffart AC, Timsit JF, Burghi G, Irrazábal C, Pattison N, et al. Intensive care in patients with lung cancer: a multinational study. Ann Oncol. 2014; 25(9):1829–35. https://doi.org/10.1093/annonc/mdu234 PMID: 24950981

6. Torres VB, Vassalo J, Silva UV, Caruso P, Torely AP, Silva E, et al. Outcomes in Critically Ill Patients with Cancer-Related Complications. PLoS One. 2016; 11(10):e0164537. https://doi.org/10.1371/journal.pone.0164537 PMID: 27764143

7. Azoulay É, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 2001; 29:519–25. PMID: 11373414

8. Pingleton SK. Complications of acute respiratory failure. The American review of respiratory disease 1988; 137:1463–93. https://doi.org/10.1164/ajrccm/137.6.1463 PMID: 3059862

9. Conti G, Marino P, Cogliati A, Dell’Utri D, Lappa A, Rosa G, et al. Noninvasive ventilation for the treatment of acute respiratory failure in patients with hematologic malignancies: a pilot study. Intensive Care Med 1998; 24:1283–8. PMID: 9885881

10. Rabbat A, Chaoui D, Montani D, Legrand O, Lefebvre A, Rio B, et al. Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol 2005; 129:350–7. https://doi.org/10.1111/j.1365-2141.2005.05459.x PMID: 15842658

11. Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay É. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008; 36:2766–72. https://doi.org/10.1097/CCM.0b013e31818699f6 PMID: 18766110

12. Gris tina GR, Antonelli M, Conti G, Ci arlone A, Rogante S, Rossi C, et al. Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med 2011; 39:2232–9. https://doi.org/10.1097/CCM.0b013e3182227a27 PMID: 21666446

13. Meert AP, Close L, Hardy M, Berghmans T, Markiewicz E, Sculier JP. Noninvasive ventilation: application to the cancer patient admitted in the intensive care unit. Support Care Cancer 2003; 11:56–9. https://doi.org/10.1007/s00520-002-0373-0 PMID: 12527955

14. Rathi NK, Haque SA, Nates R, Kosturakis A, Wang H, Dong W, et al. Noninvasive positive pressure ventilation vsinvasive mechanical ventilation as first-line therapy for acute hypoxic respiratory failure in cancer patients. J Crit Care. 2017; 39:56–61. https://doi.org/10.1016/j.jcrc.2017.01.007 PMID: 28213266

15. Ferreira JC, Medeiros P Jr, Rego FM, Caruso P. Risk factors for noninvasive ventilation failure in cancer patients in the intensive care unit: A retrospective cohort study. J Crit Care. 2015; 30(5):1003–7 https://doi.org/10.1016/j.jcrc.2015.04.121 PMID: 26072388

16. Neuschwanter A, Lemiale V, Darmon M, Péne F, Koutatchet A, Perez P, et al. Noninvasive ventilation during acute respiratory distress syndrome in patients with cancer: Trends in use and outcome. J Crit Care. 2017; 38:295–299. https://doi.org/10.1016/j.jcrc.2016.11.042 PMID: 28038339

17. OKen MM, Creech RH, Tormey D, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–55. PMID: 7165009

18. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TMM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:1049–59. https://doi.org/10.1097/JTO.0b013e3181b77f99 PMID: 19662623

19. Roques S, Parrot A, Lavole A, Ancel PY, Gounant V, Djibre M, et al. Six-month prognosis of patients with lung cancer admitted to the intensive care unit. Intensive Care Med 2009; 35:2044–50. https://doi.org/10.1007/s00134-009-1625-y PMID: 19768453

20. Adam AK, Soubani AO. Outcome and prognostic factors of lung cancer patients admitted to the medical intensive care unit. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2008; 31:47–53.

21. Andrejak C, Terzi N, Thielen S, Bergot E, Zalcman G, Charbonneau P, et al. Admission of advanced lung cancer patients to intensive care unit: a retrospective study of 76 patients. BMC Cancer 2011; 11:159. https://doi.org/10.1186/1471-2407-11-159 PMID: 21535895

22. Toffart AC, Minet C, Raynard B, Schwelbc C, Hamidfar-Roy R, Diab S, et al. Use of intensive care in patients with nonresectable lung cancer. Chest. 2011; 139(1):101–8. https://doi.org/10.1378/chest.09-2863 PMID: 20634283

23. International Consensus Conferences in Intensive Care Medicine: Noninvasive Positive Pressure Ventilation in Acute Respiratory Failure. Am J Respir Crit Care Med 2001; 163:283–91. https://doi.org/10.1164/ajrccm.163.1.ats1000 PMID: 11208659
24. Nava S, Gregoretti C, Fanfulla F, Squadrone E, Grassi M, Carlucci A, et al. Noninvasive ventilation to prevent respiratory failure after extubation in high-risk patients. Crit Care Med 2005; 33:2465–70. PMID: 16276167

25. Ferrer M, Valencia M, Nicolas JM, Bernadich O, Badia JR, Torres A. Early noninvasive ventilation averts extubation failure in patients at risk: a randomized trial. American journal of respiratory and critical care medicine 2006; 173:164–70. https://doi.org/10.1164/rccm.200505-718OC PMID: 16224108

26. El-Solh AA, Aquilina A, Pineda L, Dhanvantri V, Grant B, Bouquin P. Noninvasive ventilation for prevention of post-extubation respiratory failure in obese patients. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 2006; 28:588–95.

27. Ferrer M, Sellares J, Valencia M, Carrillo A, Gonzalez G, Badia JR, et al. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet 2009; 374:1082–8. https://doi.org/10.1016/S0140-6736(09)61038-2 PMID: 19882735

28. Burns KE, Meade MO, Premji A, Adhikari NK. Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure. The Cochrane database of systematic reviews 2013; 12:CD004127.